Utilities Registry

Filter results using search terms, or by selecting one or more valuation, condition, or population.

Valuation

Population

Condition

Viewing 1 - 10 of 44 results

Title	Year(s) of data collection	Valuation Method	Country	Condition
Selection of autoimmune disease health state utilities (Armuzzi A et al., BMC Gastroenterol. 2023. doi:10.1186/s12876-023-02640-7)	2020 - 2021	EQ-5D-5L	France, Germany, Italy, Spain, United Kingdom of Great Britain and Northern Ireland, United States of America	Ulcerative colitis
DOI 10.7910/DVN/XTLOGB Author(s) Registry, Utilities Description Health state utilities for autoimmune disease conditions Sample Characteristics a point-in-time survey of 164 matched patients treated with tofacitinib
Title Selection of autoimmune disease health state utilities (Schreiber S et al., J Crohns Colitis. 2023. doi:10.1093/ecco-jcc/jjad018)	Year(s) of data collection 2017 - 2018	Valuation Method EQ-5D	Country Argentina, Australia, Belgium, Bulgaria, Canada, Croatia, Czechia, France, Georgia, Germany, Greece, Hong Kong, Hungary, India, Ireland, Israel, Italy, Japan, Korea (Republic of), Malaysia, Mexico, Netherlands, New Zealand, Poland, Portugal, Romania, Russian Federation, Serbia, Singapore, Slovakia, South Africa, Spain, Sweden, Switzerland, Taiwan (Province of China), Ukraine, United Kingdom of Great Britain and Northern Ireland, United States of America	Condition Ulcerative colitis
DOI 10.7910/DVN/XTLOGB Author(s) Registry, Utilities Description Health state utilities for autoimmune disease conditions Sample Characteristics An RCT for filgotinib in 786 adults with moderately to severely active UC
Title Selection of orthopedic and musculoskeletal health state utilities (Hustedt JW et al., J Hand Surg Am. 2023. doi:10.1016/j.jhsa.2022.11.021)	Year(s) of data collection 2020 - 2021	Valuation Method EQ-5D	Country United States of America	Condition Thumb carpometacarpal arthritis
DOI 10.7910/DVN/VR4XYO Author(s) Registry, Utilities Description Health state utilities for orthopedic and musculoskeletal conditions Sample Characteristics A prospective clinical trial of 48 participants comparing denervation with suspension arthroplasty for treatment of carpometacarpal arthritis of the thumb
Title Selection of oncology health state utilities (Clavo B et al., Int J Environ Res Public Health. 2023. doi:10.3390/ijerph20021479)	Year(s) of data collection 2019 - 2022	Valuation Method EQ-5D-5L	Country Spain	Condition Symptomatic Cancer Survivor
DOI 10.7910/DVN/L4V2LU Author(s) Registry, Utilities Description Health state utilities for oncology conditions Sample Characteristics 26 patients with persistent or refractory side effects of cancer treatments to investigate the effects of ozone treatment
Title Selection of neurological disease health state utilities (Looby A et al., J Med Econ. 2023. doi:10.1080/13696998.2023.2189395)	Year(s) of data collection 2022	Valuation Method EQ-5D-5L	Country United Kingdom of Great Britain and Northern Ireland	Condition Spinal cord injury
DOI 10.7910/DVN/VJSSSX Author(s) Registry, Utilities Description Health state utilities for neurological disease conditions Sample Characteristics A cohort of 57 patients with spinal cord injury
Title Selection of neurological disease health state utilities (Lacy B et al., Clin Park Relat Disord. 2023. doi:10.1016/j.prdoa.2022.100180)	Year(s) of data collection 2010 - 2011	Valuation Method EQ-5D	Country United States of America	Condition Parkinson's disease
DOI 10.7910/DVN/VJSSSX Author(s) Registry, Utilities Description Health state utilities for neurological disease conditions Sample Characteristics A cross-sectional study of 124 patients with PD at an academic movement clinic
Title Selection of orthopedic and musculoskeletal health state utilities (Zhou AK et al., Eur J Orthop Surg Traumatol. 2023. doi:10.1007/s00590-022-03204-3)	Year(s) of data collection 2014 - 2021	Valuation Method EQ-5D-5L	Country United Kingdom of Great Britain and Northern Ireland	Condition Open talus fractures
DOI 10.7910/DVN/VR4XYO Author(s) Registry, Utilities Description Health state utilities for orthopedic and musculoskeletal conditions Sample Characteristics 14 participants from the review of electronic hospital records, cohort
Title Selection of autoimmune disease health state utilities (Saccà F et al., J Neurol. 2023. doi:10.1007/s00415-022-11517-w)	Year(s) of data collection 2018 - 2020	Valuation Method EQ-5D-5L	Country Belgium, Canada, Czechia, Denmark, France, Georgia, Germany, Hungary, Italy, Japan, Netherlands, Poland, Russian Federation, Serbia, United Kingdom of Great Britain and Northern Ireland, United States of America	Condition Myasthenia gravis
DOI 10.7910/DVN/XTLOGB Author(s) Registry, Utilities Description Health state utilities for autoimmune disease conditions Sample Characteristics 167 participants in phase 3 RCT of efgartigimod, ADAPT trial
Title Selection of autoimmune disease health state utilities (Dewilde S et al., Adv Ther. 2023. doi:10.1007/s12325-023-02437-w)	Year(s) of data collection 2021	Valuation Method EQ-5D-5L, HUI3	Country Belgium, Canada, Denmark, France, Germany, Italy, Japan, Netherlands, Spain, United Kingdom of Great Britain and Northern Ireland, United States of America	Condition Myasthenia gravis
DOI 10.7910/DVN/XTLOGB Author(s) Registry, Utilities Description Health state utilities for autoimmune disease conditions Sample Characteristics 9000 participants in the general population norms study that included adult patients with gMG randomly assigned to treatment with efgartigimod or conventional therapy
Title Selection of autoimmune disease health state utilities (Dewilde S et al., Adv Ther. 2023. doi:10.1007/s12325-023-02437-w)	Year(s) of data collection 2019 - 2022	Valuation Method EQ-5D-5L, HUI3	Country Canada, Denmark, France, Germany, Italy, Japan, Spain, United Kingdom of Great Britain and Northern Ireland, United States of America	Condition Myasthenia gravis
DOI 10.7910/DVN/XTLOGB Author(s) Registry, Utilities Description Health state utilities for autoimmune disease conditions Sample Characteristics 1299 participants (EQ-5D-5L) and 549 participants (HUI3) from MyRealWorld-MG study

Next results →